Advanced models for respiratory disease and drug studies.
Sign Up to like & getrecommendations! Published in 2023 at "Medicinal research reviews"
DOI: 10.1002/med.21956
Abstract: The global burden of respiratory diseases is enormous, with many millions of people suffering and dying prematurely every year. The global COVID-19 pandemic witnessed recently, along with increased air pollution and wildfire events, increases the… read more here.
Keywords: disease drug; models respiratory; respiratory disease; advanced models ... See more keywords
Statistical considerations for rare diseases drug development
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Biopharmaceutical Statistics"
DOI: 10.1080/10543406.2019.1657441
Abstract: ABSTRACT One of the most challenges for rare disease clinical trials is probably the availability of a small patient population. It is then a great concern on how to conduct clinical trials with a small… read more here.
Keywords: statistical considerations; rare diseases; rare disease; drug ... See more keywords
springD2A: capturing uncertainty in disease-drug association prediction with model integration
Sign Up to like & getrecommendations! Published in 2022 at "Bioinformatics"
DOI: 10.1093/bioinformatics/btab820
Abstract: MOTIVATION Drug repositioning that aims to find new indications for existing drugs has been an efficient strategy for drug discovery. In the scenario where we only have confirmed disease-drug associations as positive pairs, a negative… read more here.
Keywords: disease drug; drug association; drug; model ... See more keywords
A systematic review on disease‐drug‐drug interactions with immunomodulating drugs: A critical appraisal of risk assessment and drug labelling
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.15372
Abstract: Use of immunomodulating therapeutics for immune‐mediated inflammatory diseases may cause disease‐drug‐drug interactions (DDDIs) by reversing inflammation‐driven alterations in the metabolic capacity of cytochrome P450 enzymes. European Medicine Agency (EMA) and US Food and Drug Administration… read more here.
Keywords: disease drug; drug interactions; drug drug; drug labelling ... See more keywords
The economics of moonshots: Value in rare disease drug development
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Translational Science"
DOI: 10.1111/cts.13270
Abstract: The authors review the literature surrounding the economics of rare disease drug development and access before advancing the case for novel approaches to funding treatments. To fund the next stage of rare disease drugs, which… read more here.
Keywords: drug development; rare disease; economics; disease drug ... See more keywords